Tag: decisionmaking

  • Shared Decision-Making Engages Patients With Depression

    Shared Decision-Making Engages Patients With Depression

    There is a wide selection of selections obtainable to take care of depression. But that does not automatically make it less complicated for about a 3rd of grownup clients with melancholy to overcome the issue, which can be serious for lots of.

    For around 2.8 million persons—or 1.1 percent of the grownup inhabitants in the United States—treatment-resistant despair (TRD) is a actuality.

    It also can be complicated to arrive by a clear definition of the problem, although the Foods and Drug Administration “considers clients to have TRD if they have big depressive disorder and, even with at the very least two trials of antidepressant treatment presented at suitable doses for an sufficient duration in the present episode, they have not responded to treatment.”

    Two unsuccessful classes of medicine can come to feel endless to someone who’s struggling. Those people tries signify time put in battling. Trying to get, striving, and failing to control despair can be draining and chip away at hope. But when sufferers operate with suppliers who embrace shared decision-building to discover cure alternatives, it can improve the program of melancholy and make a beneficial variance.

    The ability of shared choice-generating

    Shared conclusion-earning involves overall health care companies and clients working jointly to identify certain treatment ambitions and talk about how to attain them. Clients do not passively undergo treatment method they enjoy a significant position in their care.

    Which includes clients in their have treatment may perhaps make it more probable that they’ll entire therapy homework and adhere to a medicine routine, 1 report has identified. Shared choice-generating can aid the progress of far more productive treatment method plans, which is critical with a serious affliction that necessitates ongoing participation and investment decision.

    It adds a layer of complexity when depression will become therapy-resistant. Sufferers currently have exhausted some procedure choices, and other people could demand more recent techniques or a wide variety of tactics, just about every of which necessitates a different patient commitment.

    With numerous choice treatment options now out there for TRD, thoughts abound. The cure choices vary from psychotherapy, trials of medications or a mixture of prescription drugs, and newer psychedelic agents these as ketamine and mind stimulation.

    Can ketamine support?

    Ketamine is a medicine generally utilised for anesthesia. However, in sub-anesthetic doses, it has emerged as an interesting new treatment method for TRD (and suicidality), typically with a incredibly immediate reaction price. To know whether ketamine is appropriate for a patient, it’s significant for patients to think about the subsequent questions with a experienced, reliable health care, mental wellness husband or wife.

    How does ketamine operate?

    Ketamine, which is Fda-permitted when supplied as a nasal spray, may well support develop synapses (connections) in the mind that are dropped since of melancholy. It also may perhaps activate a neurotransmitter called glutamate in the brain.

    How is ketamine administered?

    Ketamine is specified to clients both intranasally or intravenously. Clinical supervision is essential when a affected individual is undergoing ketamine treatment options.

    When patients are offered ketamine nasally, it is typically finished 2 times a week for a person to 4 months and is protected by insurance. After that, it is provided weekly for another four months and goes down to the moment each individual other week. Clients getting ketamine intranasally can still be on an antidepressant.

    Intravenous infusions, which are generally not covered by insurance plan, come about on a different schedule. To start, they’re ordinarily administered six instances in excess of the training course of three weeks. Sufferers on ketamine infusions aren’t typically getting antidepressants, also. Infusions are generally more effective than ketamine taken by using a nasal inhaler.

    What are the aspect effects of taking ketamine?

    Some patients who take ketamine expertise transient thoughts of unreality, sensory distortions, a sense-very good “buzz,” sedation, and a attainable blood tension improve.

    Discovering mind stimulation

    Brain stimulation is one more effective remedy for TRD. The oldest form of brain stimulation is electroconvulsive treatment (ECT). Inspite of inaccurate depictions of the treatment method, ECT has a 50-70 p.c response amount. Disadvantages can contain that it needs anesthesia and might cause facet consequences these as short-term memory deficits, critical factors that providers and people need to explore.

    Melancholy Important Reads

    Affected individual-provider teams also may want to go over temporal magnetic stimulation (TMS), a sort of mind stimulation that has been Food and drug administration-authorized to handle melancholy for about two decades. With about 60 p.c response amount, it’s not as productive as ECT, but it does not demand anesthesia. This entails individuals wearing a equipped hat that triggers a tapping feeling on the scalp for every 40- to 45-moment session—typically four or 5 periods per week for many months. Wellbeing insurance policy firms largely protect TMS.

    When conclusion-making is shared, these treatment options may perhaps be applied alongside other individuals, such as medicine and, of class, converse treatment. Though most medicines by itself are about 60 percent productive, they may be additional helpful when people and companies discover an substitute treatment or a mix of treatments that performs for that personal patient’s despair.

    With so many potential treatments on the sector, it’s critical for patients suffering from procedure-resistant melancholy to have a proficient, reliable companion. Individuals frequently need suppliers who will enable map out prognosis, cure, and restoration in a detailed way. Nevertheless some people may well come to feel powerless around their issue, shared conclusion-building has the probable to assistance them regain some of that electrical power so they can have interaction in their own procedure and in their potential.

  • 1.

    Nelson HD. Menopause. Lancet. 2008;371(9614):760–70.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 2.

    Natari RB, Clavarino AM, McGuire TM, Dingle KD, Hollingworth SA. The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. Menopause. 2018;25(1):109–20.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 3.

    Schbley BH. Socioeconomic factors in menopausal women’s use of hormone replacement therapy. J Women Aging. 2009;21(2):99–110.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 4.

    Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health. 2013;22(11):983–90.

    Article 

    Google Scholar
     

  • 5.

    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

    Article 

    Google Scholar
     

  • 6.

    Committee TWHIS. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.

    Article 

    Google Scholar
     

  • 7.

    Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328(15):1069–75.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 8.

    Stoppe G, Dören M. Critical appraisal of effects of estrogen replacement therapy on symptoms of depressed mood. Arch Women Ment Health. 2002;5(2):39–47.

    CAS 
    Article 

    Google Scholar
     

  • 9.

    Brown S. Shock, terror and controversy: how the media reacted to the Women’s health initiative. Climacteric. 2012;15(3):275–80.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 10.

    Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women’s Health Initiative: cross sectional survey of users. BMJ. 2003;327(7419):845.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 11.

    Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 12.

    de Villiers TJ, Hall JE, Pinkerton JV, Cerdas Perez S, Rees M, Yang C, Pierroz DD. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–5.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 13.

    Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2005;14(3):171–6.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 14.

    Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013;103(9):1583–8.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 15.

    LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–14.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 16.

    Bahri N, Pourali L, Esmaeeli H. Application of various menopausal symptoms treatment options and its related factors, Gonabad- 2016. Iran J Obstet Gynecol Infert. 2016;19(26):1–8.


    Google Scholar
     

  • 17.

    Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus. 2015;4(1):65.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 18.

    Goldstein KM, Coeytaux RR, Williams JW Jr, Shepherd-Banigan M, Goode AP, McDuffie JR, Befus D, Adam S, Masilamani V, Van Noord MG. Non-pharmacologic treatments for menopause-associated vasomotor symptoms. Washington DC: DVA Health Services Research and Development Service; 2016.


    Google Scholar
     

  • 19.

    Carpenter JS, Byrne MM, Studts JL. Factors related to menopausal symptom management decisions. Maturitas. 2011;70(1):10–5.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 20.

    Siyam T, Carbon J, Ross S, Yuksel N. Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): a narrative review. Maturitas. 2019;120:68–76.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 21.

    Hyde A, Nee J, Drennan J, Butler M, Howlett E. Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause. 2010;17(2):344–50.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 22.

    Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318(10):927–38.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 23.

    Langer RD, Hodis HN, Lobo RA, Allison MA. Hormone replacement therapy—where are we now? Climacteric. 2021;24(1):3–10.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 24.

    Thompson JJ, Ritenbaugh C, Nichter M. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health. 2017;17(1):97.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 25.

    Velentzis LS, Banks E, Sitas F, Salagame U, Tan EH, Canfell K. Use of menopausal hormone therapy and bioidentical hormone therapy in Australian women 50 to 69 years of age: results from a national, cross-sectional study. PLoS ONE. 2016;11(3):e0146494.

    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 26.

    Bahri N, Sajjadi M, Sadeghmoghadam L. The relationship between management strategies for menopausal symptoms and women’s decision making styles during menopausal transition. Prz Menopauzalny. 2019;18(3):174–9.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 27.

    Theroux R. Women’s decision making during the menopausal transition. J Am Acad Nurse Pract. 2010;22(11):612–21.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 28.

    Zapata AML, Beaudreau SA, O’Hara R, Bereknyei Merrell S, Bruce J, Garrison-Diehn C, Gould CE. Information-seeking about anxiety and perceptions about technology to teach coping skills in older veterans. Clin Gerontol. 2017;41(8):346–56.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, Gudeman J, Krop J, Simon JA. Female sexual health: barriers to optimal outcomes and a roadmap for improved patient-clinician communications. J Women’s Health (2002). 2019;28(4):432–43.

    Article 

    Google Scholar
     

  • 30.

    Henwood F, Wyatt S, Hart A, Smith J. ‘Ignorance is bliss sometimes’: constraints on the emergence of the ‘informed patient’ in the changing landscapes of health information. Sociol Health Illn. 2003;25(6):589–607.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 31.

    Pache DM, Hollingworth SA, van Driel ML, McGuire TM. Does consumer medicines interest reflect medicines use? An Australian observational study comparing medicines call center queries with medicines use. Res Social Adm Pharm. 2019;15(4):440–7.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 32.

    Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, Committee RW. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 33.

    ATC/DDD Index 2017 https://www.whocc.no/atc_ddd_index/

  • 34.

    Commonwealth Department of Health and Aged Care, National Key Centre for Social Applications of Geographical Information Systems: Measuring remoteness: Accessibility/Remoteness Index of Australia (ARIA) revised edition: Commonwealth Department of Health and Aged Care; 2001.

  • 35.

    Australian Bureau of Statistics: Year book Australia 2012. Canberra: Australian Bureau of Statistics; 2012.

  • 36.

    Beasley TM, Schumacker RE. Multiple regression approach to analyzing contingency tables: Post hoc and planned comparison procedures. J Exp Educ. 1995;64(1):79–93.

    Article 

    Google Scholar
     

  • 37.

    Bazeley P. Analysing qualitative data: More than ‘identifying themes.’ Malays J Qual Res. 2009;2(2):6–22.


    Google Scholar
     

  • 38.

    Pines A, Sturdee DW, Birkhäuser MH, Schneider HPG, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10(3):181–94.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 39.

    Hengen KM, Alpers GW. What’s the risk? Fearful Individuals generally overestimate negative outcomes and they dread outcomes of specific events. Front Psychol. 2019;10:1676.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 40.

    Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull. 2001;127(2):267–86.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 41.

    Shapiro M. Media and education of the consumer. Menopause. 2016;23(8):924–7.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 42.

    Natari RB, McGuire TM, Baker PJ, Clavarino AM, Dingle KD, Hollingworth SA. Longitudinal impact of the Women’s health initiative study on hormone therapy use in Australia. Climacteric. 2019;22(5):489–97.

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 43.

    Crawford SL, Crandall CJ, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, Joffe H. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s health initiative study results. Menopause. 2018;26(6):588–97.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 44.

    Ettinger B, Wang SM, Leslie RS, Patel BV, Boulware MJ, Mann ME, McBride M. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2018;25(11):1306–12.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 45.

    Kloosterboer SM, McGuire T, Deckx L, Moses G, Verheij T, van Driel ML. Self-medication for cough and the common cold: Information needs of consumers. Aust Fam Physician. 2015;44(7):497–501.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 46.

    Gartoulla P, Davis S, Worsley R, Bell R. Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40–65 years. Med J Aust. 2015;203(3):146–146.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 47.

    de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global Consensus Statement on menopausal hormone therapy. Maturitas. 2013;74(4):391–2.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 48.

    Huston SA, Jackowski RM, Kirking DM. Women’s trust in and use of information sources in the treatment of menopausal symptoms. Womens Health Issues. 2009;19(2):144–53.

    PubMed 
    Article 
    PubMed Central 

    Google Scholar